Transgene Biotek

{
  "main_header": {
    "sid": 408336,
    "name": "Transgene Biotek",
    "stock_name": "Transgene Biotek",
    "full_name": "Transgene Biotek Ltd",
    "name_url": "stocks-analysis/transgene-biotek",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "2.08",
    "chg": -0.18,
    "chgp": "-7.96%",
    "dir": -1,
    "prev_price": "2.26",
    "mcapval": "17.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 526139,
    "symbol": "",
    "ind_name": "Healthcare Services",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE773D01018",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "90.09 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/transgene-biotek-408336-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "When is the next results date for Transgene Biotek Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-transgene-biotek-ltd-3810211",
        "imagepath": "",
        "date": "2026-01-29 23:15:54",
        "description": "The next results date for Transgene Biotek Ltd is scheduled for 13 February 2026...."
      },
      {
        "title": "Why is Transgene Biotek falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-transgene-biotek-fallingrising-3757684",
        "imagepath": "",
        "date": "2025-12-13 00:55:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Despite the recent surge, Transgene Biotek’s stock remains under pressure over longer time horizons. Year-to-date, the stock has declined by 56.22%, significantly underperforming the Sensex, which has gained 9.12% during the same period. Over the past year, the stock has fallen by 57.89%, contrasting with the Sensex’s 4.89% rise. Even over five years, the stock has declined by 41.83%, while the benchmark index has appreciated by nearly 85%. These figures highlight the challenges the company has faced in maintaining investor confidence over time.</p>\n<p>However, the recent price action on 12-Dec marks a reversal from a short-term downtrend. After three consecutive days of declines, the stock’s 9.93% gain indicates renewed buying interes..."
      },
      {
        "title": "How has been the historical performance of Transgene Biotek?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-transgene-biotek-3702753",
        "imagepath": "",
        "date": "2025-11-14 23:31:50",
        "description": "Answer:\nThe historical performance of Transgene Biotek shows a gradual increase in net sales, rising from 0.06 Cr in Mar'23 to 0.26 Cr in Mar'25. However, the company has consistently reported negative operating profits, with an operating profit of -1.13 Cr in Mar'25, indicating a worsening trend compared to -0.62 Cr in Mar'24. The total expenditure has also increased significantly, reaching 1.39 Cr in Mar'25 from 0.85 Cr in Mar'24. The profit before tax has remained negative, with a loss of -0.68 Cr in Mar'25, slightly worse than -0.66 Cr in Mar'24. The net profit after tax also reflects this trend, showing a loss of -0.68 Cr in Mar'25 compared to -0.66 Cr in Mar'24. The company's total liabilities have remained relatively stable at 142.33 Cr in Mar'24, down from 142.36 Cr in Mar'23. The cash flow from operating activities has been stagnant, with no cash inflow reported in recent years.\n\nBreakdown:\nTransge..."
      },
      {
        "title": "Why is Transgene Biotek falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-transgene-biotek-fallingrising-3686779",
        "imagepath": "",
        "date": "2025-11-10 21:20:52",
        "description": "As of 10-Nov, Transgene Biotek Ltd's stock price is currently at 3.84, reflecting an increase of 0.33 or 9.4%. The stock has shown a positive performance today, outperforming its sector by 10.98% and has been on a consecutive gain for the last two days, accumulating a total return of 13.27% during this period. However, despite this recent uptick, the stock has experienced a significant decline year-to-date of 43.78% and a 1-month drop of 7.69%. The stock's delivery volume has decreased by 2.05% compared to the 5-day average, indicating a falling investor participation, which may temper the positive momentum. Unfortunately, there is no information available regarding positive or negative factors that could further explain the stock's recent movement.\n\nIn the broader market context, Transgene Biotek's short-term return of +1.05% over the past week contrasts with the Sensex, which has declined by 0.53% during ..."
      },
      {
        "title": "Why is Transgene Biotek falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-transgene-biotek-fallingrising-3676529",
        "imagepath": "",
        "date": "2025-11-06 21:16:53",
        "description": "As of 06-Nov, Transgene Biotek Ltd's stock price is currently at Rs 3.36, reflecting a decline of Rs 0.22 or 6.15%. The stock has been underperforming, having lost 11.58% over the last two days and is trading below all key moving averages, indicating a bearish trend. Additionally, it is 4.46% away from its 52-week low of Rs 3.21. In terms of performance relative to the benchmark, the stock has seen significant declines, with a year-to-date drop of 50.81%, while the Sensex has gained 6.62% during the same period. Although there has been a notable increase in investor participation, with delivery volume rising by 79.97% against the 5-day average, the overall sentiment remains negative.\n\nBroader Market Context: In the short term, Transgene Biotek's performance has been markedly worse than the Sensex, which has only declined by 1.30% over the past week, while Transgene Biotek has dropped by 10.16%. This stark c..."
      }
    ],
    "total": 79,
    "sid": "408336",
    "stock_news_url": "https://www.marketsmojo.com/news/transgene-biotek-408336"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Friday 13Th February 2026",
      "datetime": "28-Jan-2026",
      "details": "Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve 1) To consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 31st December 2025. 2) To consider and approve the Limited Review Report (Standalone & Consolidated) for the quarter ended 31st December 2025. 3) To transact such other business as may be required.",
      "source": "BSE"
    },
    {
      "caption": "Statement Of Deviation & Variation",
      "datetime": "12-Jan-2026",
      "details": "Statement of Deviation & Variation",
      "source": "BSE"
    },
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "12-Jan-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Transgene Biotek Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85195TG1990PLC011065</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: ANKITA JAIN <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: cs@transgenebiotek.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: PRASAD CHOWDARY <br/> Designation: CFO <br/> EmailId: cs@transgenebiotek.com</div> </div> <div> <br/> Date: 12/01/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "13 Feb 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

When is the next results date for Transgene Biotek Ltd?

2026-01-29 23:15:54

The next results date for Transgene Biotek Ltd is scheduled for 13 February 2026....

Read full news article

Why is Transgene Biotek falling/rising?

2025-12-13 00:55:49

Recent Price Movement and Market Context

Despite the recent surge, Transgene Biotek’s stock remains under pressure over longer time horizons. Year-to-date, the stock has declined by 56.22%, significantly underperforming the Sensex, which has gained 9.12% during the same period. Over the past year, the stock has fallen by 57.89%, contrasting with the Sensex’s 4.89% rise. Even over five years, the stock has declined by 41.83%, while the benchmark index has appreciated by nearly 85%. These figures highlight the challenges the company has faced in maintaining investor confidence over time.

However, the recent price action on 12-Dec marks a reversal from a short-term downtrend. After three consecutive days of declines, the stock’s 9.93% gain indicates renewed buying interes...

Read full news article

How has been the historical performance of Transgene Biotek?

2025-11-14 23:31:50

Answer: The historical performance of Transgene Biotek shows a gradual increase in net sales, rising from 0.06 Cr in Mar'23 to 0.26 Cr in Mar'25. However, the company has consistently reported negative operating profits, with an operating profit of -1.13 Cr in Mar'25, indicating a worsening trend compared to -0.62 Cr in Mar'24. The total expenditure has also increased significantly, reaching 1.39 Cr in Mar'25 from 0.85 Cr in Mar'24. The profit before tax has remained negative, with a loss of -0.68 Cr in Mar'25, slightly worse than -0.66 Cr in Mar'24. The net profit after tax also reflects this trend, showing a loss of -0.68 Cr in Mar'25 compared to -0.66 Cr in Mar'24. The company's total liabilities have remained relatively stable at 142.33 Cr in Mar'24, down from 142.36 Cr in Mar'23. The cash flow from operating activities has been stagnant, with no cash inflow reported in recent years. Breakdown: Transge...

Read full news article

Why is Transgene Biotek falling/rising?

2025-11-10 21:20:52

As of 10-Nov, Transgene Biotek Ltd's stock price is currently at 3.84, reflecting an increase of 0.33 or 9.4%. The stock has shown a positive performance today, outperforming its sector by 10.98% and has been on a consecutive gain for the last two days, accumulating a total return of 13.27% during this period. However, despite this recent uptick, the stock has experienced a significant decline year-to-date of 43.78% and a 1-month drop of 7.69%. The stock's delivery volume has decreased by 2.05% compared to the 5-day average, indicating a falling investor participation, which may temper the positive momentum. Unfortunately, there is no information available regarding positive or negative factors that could further explain the stock's recent movement. In the broader market context, Transgene Biotek's short-term return of +1.05% over the past week contrasts with the Sensex, which has declined by 0.53% during ...

Read full news article

Why is Transgene Biotek falling/rising?

2025-11-06 21:16:53

As of 06-Nov, Transgene Biotek Ltd's stock price is currently at Rs 3.36, reflecting a decline of Rs 0.22 or 6.15%. The stock has been underperforming, having lost 11.58% over the last two days and is trading below all key moving averages, indicating a bearish trend. Additionally, it is 4.46% away from its 52-week low of Rs 3.21. In terms of performance relative to the benchmark, the stock has seen significant declines, with a year-to-date drop of 50.81%, while the Sensex has gained 6.62% during the same period. Although there has been a notable increase in investor participation, with delivery volume rising by 79.97% against the 5-day average, the overall sentiment remains negative. Broader Market Context: In the short term, Transgene Biotek's performance has been markedly worse than the Sensex, which has only declined by 1.30% over the past week, while Transgene Biotek has dropped by 10.16%. This stark c...

Read full news article

View All News